Can Women Take Finasteride (Propecia) for Thinning Hair?

A widening part, more scalp showing under bright light, and a forum post saying finasteride worked for someone’s sister. The Propecia label gives a clear starting point for women: it is not approved for you, and it carries a pregnancy contraindication. The research adds nuance, and dermatologists sometimes discuss it anyway.

Bathroom vanity in soft morning light with a wide-tooth comb, a folded hand towel and a plain unlabeled amber bottle on a white counter, mint walls, no people

Start with the Propecia prescribing information on DailyMed. Its indication section says Propecia is for male pattern hair loss (androgenetic alopecia) “in MEN ONLY,” and then states directly: “PROPECIA is not indicated for use in women.”

The contraindications section goes further. Finasteride use is “contraindicated in women when they are or may potentially be pregnant.” The reason is biological: finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT), a hormone a male fetus needs for normal genital development, and the label says it may cause abnormalities of the external genitalia of a male fetus.

There is even a handling rule. The label says women “should not handle crushed or broken PROPECIA tablets when they are pregnant or may potentially be pregnant,” because the drug could be absorbed. It adds that the tablets are coated, which prevents contact with the active ingredient during normal handling as long as they are not broken or crushed.

Where that leaves women

Using finasteride for female pattern hair loss is off label. The one placebo-controlled trial cited on the label, in postmenopausal women, found no benefit. Some later, smaller and mostly uncontrolled studies using other doses or combinations report improvement. Because of the pregnancy risk, any discussion of it belongs with a dermatologist, and the American Academy of Dermatology lists other options first, including minoxidil, which the FDA has approved for women.

What the studies in women found

Research on finasteride in women is smaller and weaker than the research in men. The table summarizes the main trials and reviews we could open, with the limits their authors stated.

Study	Who was studied	What was tested	Result	Limits
Price et al., J Am Acad Dermatol 2000	137 postmenopausal women aged 41–60	Finasteride 1 mg/day or placebo for 1 year	No difference in hair count; no improvement on photos, assessments or biopsies	Only postmenopausal women; one dose studied
Cochrane review, 2016	47 trials of hair-loss treatments in women, 5,290 participants	Pooled three finasteride 1 mg vs. placebo studies	“Finasteride was no more effective than placebo”	Low-quality evidence for this comparison
Iorizzo et al., Arch Dermatol 2006	37 premenopausal women	Finasteride 2.5 mg/day while taking a drospirenone/ethinyl estradiol birth control pill	62% showed some improvement at 12 months	No placebo group; authors could not tell whether the higher dose or the antiandrogenic pill drove the result
Hu et al., Int J Dermatol 2019	65 studies, 2,683 women and girls, for several conditions	Oral doses from 0.5 to 5 mg/day	Non-randomized studies report possible improvement in pattern hair loss	Authors call for long-term studies on effects and consequences
Nobari et al., Adv Clin Exp Med 2023	14 studies in women of reproductive age and after menopause	Oral or topical finasteride, alone or combined	10 of 14 reported a high rate of improvement; authors suggest 5 mg/day may help normoandrogenic women, especially in combination	Small number of studies of mixed design

Doses in this table describe what researchers tested. They are not guidance for anyone’s own use.

The pattern across these papers is fairly consistent. The trials with a placebo group, which tested the 1 mg dose used for men, did not show a benefit in women. Positive reports tend to come from studies that used higher doses, combined finasteride with other treatments, or had no placebo group. That makes them hypotheses worth testing rather than settled answers. The Cochrane authors specifically listed finasteride at different dosages among treatments that need further randomized trials.

Topical finasteride sometimes comes up as well. A 2022 review (Gupta and Talukder) notes that topical finasteride is not FDA-approved, though it can lower both scalp and blood DHT levels. Lower systemic exposure is the goal, but the pregnancy concern behind the label does not simply disappear with a different form.

The pregnancy risk, in the label’s words

Propecia is contraindicated for women who are or may become pregnant. The label explains that DHT is necessary for normal development of male genitalia, that finasteride caused abnormal external genitalia in male fetuses in animal studies, and that abnormal male genital development is an expected consequence of blocking that conversion. Pregnant women, and women who could become pregnant, should not handle crushed or broken tablets. On breastfeeding, the label says it is not known whether finasteride passes into human milk. The AAD says the prescription pills dermatologists may use for female pattern hair loss, finasteride among them, “may cause birth defects,” and that dermatologists recommend birth control for premenopausal women taking one.

Why a drug that works in men may not work the same way in women

Finasteride inhibits type 2 5-alpha-reductase and lowers DHT in the blood and scalp, as the Price trial authors summarize. In men with pattern hair loss, that mechanism translates into measurable regrowth: the Propecia label reports hair-count gains over placebo across ethnic groups in its male trials. The 2000 trial in women was designed because, as its authors wrote, the effects of finasteride in women with androgenetic alopecia had not been evaluated.

Its conclusion was that, in postmenopausal women, finasteride 1 mg/day for 12 months did not increase hair growth or slow the progression of thinning. Researchers have since asked whether dose, hormone status or combination with other treatments changes the picture, which is why the later studies look so different from one another.

The label also sets expectations that apply to anyone using the drug: in men, daily use for three months or more is generally needed before benefit is seen, and stopping leads to reversal of the effect within 12 months.

When a dermatologist might raise it

None of this means finasteride is never discussed with women. The AAD’s page on female pattern hair loss lists finasteride, flutamide and dutasteride as medicines a dermatologist may prescribe. In practice, the conversation usually depends on a few things the dermatologist weighs:

Pregnancy potential. The label contraindication makes this the first question. Being postmenopausal, or using reliable contraception as the AAD describes, changes the risk discussion. It does not change the off-label status.
The evidence for your situation. The best-designed trial in postmenopausal women was negative at 1 mg, which is part of why studies of other approaches exist.
Diagnosis. Thinning has many causes. Our overview of pattern hair loss in men and women covers how it is diagnosed, and treatment choice follows the diagnosis.
Side effects and monitoring. The label’s side-effect data come from men. Our page on finasteride side effects, fertility and pregnancy handling explains the labeled effects and how household exposure is handled.

If finasteride is ever part of the plan, the choice to use it, the form and the follow-up belong to the dermatologist. This page is not a case for or against it.

What the AAD lists for women

The AAD’s female pattern hair loss page describes several options:

Minoxidil. The AAD says the FDA has approved this non-prescription treatment for women and that products with 2% or 5% minoxidil are approved for female pattern hair loss. The 2016 Cochrane review found evidence supporting topical minoxidil, with no difference between the 2% and 5% strengths. The AAD advises avoiding minoxidil during pregnancy, when planning a pregnancy, and while breastfeeding.
Spironolactone. Described by the AAD as a diuretic that has been prescribed for decades to treat hair loss.
Other prescription pills. Finasteride, flutamide or dutasteride, with the birth-defect warning above.
Platelet-rich plasma. Preliminary research the AAD calls promising, with more study needed.
Laser devices and hair transplants. The AAD notes FDA-cleared laser combs and helmets, and transplant as an option for some women.

A 2023 review in Anais Brasileiros de Dermatologia (Müller Ramos et al.) describes topical minoxidil as the only medication with a high level of evidence for female pattern hair loss and the first choice, while noting that about 40% of patients do not improve with it. Any treatment takes time to judge; our hair-loss treatment timeline explains why early shedding and slow progress are common.

Questions to bring to a dermatologist

Question	Why it matters
Is this female pattern hair loss, or could something else be causing it?	Treatment depends on the diagnosis.
Have we tried, or ruled out, the AAD’s first options such as minoxidil?	Minoxidil has the strongest evidence and is FDA-approved for women.
If finasteride comes up, what evidence supports it for someone like me?	The placebo-controlled trial at 1 mg in postmenopausal women was negative.
What does my pregnancy potential mean for this choice, and what contraception would you want?	Pregnancy is a label contraindication, and the AAD recommends birth control with these pills before menopause.
Someone in my home takes finasteride. How should tablets be stored and handled?	The label warns against handling crushed or broken tablets during or before a possible pregnancy.
How will we judge whether a treatment is working, and when?	Results take months to assess, so a set review point helps avoid judging too early.

Sources

Evidence checked November 2, 2026. Off-label use is a decision for a dermatologist who knows your history; this page does not recommend starting, stopping or changing any treatment.